Results 21 to 30 of about 31,793 (243)

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

Platelets, 2022
The benefits of potent antithrombotic therapy usually come at the expense of a higher risk of bleeding. The efficacy and safety of ticagrelor in elderly East Asian populations remains debated due to the concerns about the imbalance of ischemic and ...
Ziwei Xi, Zifeng Qiu, Jianan Li, Hong Qiu, Tingting Guo, Yong Wang, Jianfeng Zheng, Yanan Gao, Runlin Gao   +8 more
doaj   +1 more source

Stroke following percutaneous coronary intervention : type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12 [PDF]

, 2016
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015.
Berry, Colin, British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research, Buchan, Iain, de Belder, Mark A, Keavney, Bernard, Kontopantelis, Evangelos, Kwok, Chun Shing, Ludman, Peter F, Mamas, Mamas A, Myint, Phyo K, Nolan, Jim, Zaman, Azfar   +11 more
core   +1 more source

Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease

Platelets, 2019
We performed this study to observe the effects of different doses of ticagrelor and standard-dose clopidogrel on platelet reactivity and endothelial function in diabetic patients with stable coronary artery disease (CAD).
Meijiao He, Dan Li, Yingli Zhang, Danghui Sun, Guangzhong Liu, Yujiao Pan, Jing Shi, Yanyan Li, Shuangli Yin, Yue Li   +9 more
doaj   +1 more source

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome [PDF]

, 2019
Objective: To assess whether cardiovascular events are increased after cessation of dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) and to explore predictors for recurrent events after DAPT cessation during long-term follow-up.
Berry, Colin, Dawson, Jesse, Mazlan-Kepli, Wardati, Walters, Matthew   +3 more
core   +1 more source

Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression [PDF]

, 2016
The P2Y12 antagonist ticagrelor reduces mortality in patients with acute coronary syndrome (ACS), compared with clopidogrel, and the mechanisms underlying this effect are not clearly understood.
Akhmedov, Alexander, Beer, Juerg H., Bonetti, Nicole R., Camici, Giovanni G., Gaul, Daniel S., Glanzmann, Martina, Keller, Stephan, Lüscher, Thomas F., Matter, Christian M., Reiner, Martin F., Ruf, Wolfram, Savarese, Gianluigi, Stivala, Simona, Yang, Zhihong, Zhu, Cuicui   +14 more
core   +1 more source

A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor. [PDF]

PLoS ONE, 2015
Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was found in patients with acute coronary syndrome. Ticagrelor, an oral platelet ADP P2Y12 receptor antagonist, is widely used in these patients.
Yi Mao, Yudong Peng, Qiutang Zeng, Longxian Cheng, Boyuan Wang, Xiaobo Mao, Kai Meng, Yuzhou Liu, Yitian Lian, Dazhu Li   +9 more
doaj   +1 more source

The Use of Prasugrel and Ticagrelor in Pipeline Flow Diversion [PDF]

, 2018
Background: Despite the routine clopidogrel/aspirin anti-platelet therapy, complications like thromboembolism, continue to be encountered with PED.
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Eller, MD, Gorge, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA MD, Robert H., Saad, MD, Hassan, Stidd, MD, David, Tjoumakaris, MD, Stavropoula   +9 more
core   +2 more sources

Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1

Frontiers in Cardiovascular Medicine, 2023
Doxorubicin (Dox) is a widely used clinical drug whose cardiotoxicity cannot be ignored. Pyroptosis (inflammatory cell death) has gradually gained attention in the context of Dox-induced cardiotoxicity.
Shu-hui Wang, Meng-jin Sun, Si-yue Ding, Chun-li Liu, Jing-min Wang, Sheng-na Han, Xi Lin, Qian Li   +7 more
doaj   +1 more source